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In childhood acute lymphoblastic leukemia, treatment failure is associated with resistance to glucocorticoid agents. Resistance to
this class of drugs represents one of the strongest indicators of poor clinical outcome. We show that leukemic cells, which are
resistant to the glucocorticoid drug methylprednisolone, display a higher demand of glucose associated with a deregulation of
metabolic pathways, in comparison to sensitive cells. Interestingly, a combinatorial treatment of glucocorticoid and the glucose
analog 2-deoxy-D-glucose displayed a synergistic eﬀect in methylprednisolone-resistant cells, in an oxygen tension-independent
manner. Unlike solid tumors, where 2-deoxy-D-glucose promotes inhibition of glycolysis by hexokinase II exclusively under
hypoxic conditions, we were able to show that the antileukemic eﬀects of 2-deoxy-D-glucose are far more complex in leukemia.
We demonstrate a hexokinase II-independent cell viability decrease and apoptosis induction of the glucose analog in leukemia.
Additionally, due to the structural similarity of 2-deoxy-D-glucose with mannose, we could conﬁrm that the mechanism by
which 2-deoxy-D-glucose predominantly acts in leukemia is via modiﬁcation in N-linked glycosylation, leading to endoplasmic
reticulum stress and consequently induction of the unfolded protein response.
1. Introduction
Acute lymphoblastic leukemia (ALL) is the second most
common cause of death in children and adolescents, behind
accidents. Signiﬁcant advances have been made in the
successful treatment of childhood-ALL (ch-ALL), leading to
an overall survival rate approaching 90% in children [1].
Despite this success, a subset of patients remains refractory
to chemotherapy and suﬀers from relapse which is associated
with poor outcome. The conventional ch-ALL treatment
consists of several classes of chemotherapeutic agents includ-
ing glucocorticoids (GCs) and fails in approximately 20% of
the patients [2–4]. Resistance to GCs, such as methylprednis-
olone (MP), is related to unfavorable prognosis. Therefore, it
is important to develop alternative therapies that can over-
come MP resistance. Previous reports have suggested that
leukemic cells from ALL patients resistant to GC treatment
present an increase in glycolytic rate [5, 6]. Moreover, it has
been shown that solid tumors have altered rates of glucose
transport and glycolysis in comparison to their nonmalig-
nant counterparts [7–10]. The treatment of ch-ALL with
the glycolysis inhibitor 2-deoxy-D-glucose (2-DG) provided
the ﬁrst evidence that ALL have a similar metabolic shift as
solid tumors [11]. 2-DG has been extensively described to
competitively inhibit hexokinase (HK) and glucose phos-
phoisomerase (PGI) in solid tumors [12]. Indeed, 2-DG can
enter into the cell through glucose transporter GLUT-1,
where it is converted to 2-deoxy-D-glucose-6-phosphate
(2-DG6P) by HK. Unlike the endogenous substrate, G6P,
2-DG6P cannot be further metabolized by the second enzyme
in the glycolytic pathway, PGI. It has been shown that in solid
tumors, 2-DG6P accumulation inhibits glycolysis which
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represents the main mechanism of 2-DG cytotoxicity [13].
Furthermore, it has been previously reported that in cancer
cells growing under hypoxic conditions, 2-DG causes
apoptosis by inhibiting glycolysis [12]. In this study, we
demonstrate that, in contrast to solid tumors, 2-DG induces
apoptosis in ch-ALL cell lines in combination with MP
under normal oxygen tension. In addition, we report that
the cytotoxic activity of 2-DG in leukemia cell line is not
primary through glycolysis inhibition, since silencing of
HKII does not interfere with 2-DG-mediated decrease in
cell viability. We hypothesize that, in leukemia cells, 2-DG
predominantly acts as an inhibitor of N-linked glycosyla-
tion (NLG) due to its structural similarity with mannose.
2-DG can be fraudulently incorporated in the place of man-
nose on the oligosaccharide chain and lead to accumulation
of misfolded proteins [12]. The accumulation of misfolded
proteins in the lumen of the endoplasmic reticulum (ER)
leads to ER stress and, as a consequence, the induction of
the unfolded protein response (UPR) [13]. Taken together,
the cytotoxic activity of 2-DG in selected ch-ALL cells
under aerobic conditions is caused by interfering with
NLG rather than inhibition of glycolysis. Furthermore, we
discovered an additional mechanism of 2-DG action, which
involves glycogen synthase kinase-3 (GSK-3) in the context
of MP resistance in ch-ALL cell lines.
2. Material and Methods
2.1. Calculation of Synergy. Synergistic eﬀects of drugs were
evaluated as equipotent drug concentrations by the equation
developed by Berenbaum [14]. A dose-response curve was
constructed for each single drug and combinations of two
drugs together. The values calculated according to the
Berenbaum equation are referred to as a synergy factor (Fsyn).
A value< 1 indicates synergy, Fsyn equal to 1 indicates an
additive eﬀect, and Fsyn> 1 represents an antagonist eﬀect.
2.2. Glucose-Consumption Assay. Glucose levels were mea-
sured with the glucose assay kit (Sigma, Buchs, Switzerland),
as described by the manufacturer. Brieﬂy, 5× 105 cells were
cultured and after 96 h medium was collected and incubated
for 30 minutes with glucose assay buﬀer (1.5mM NAD,
1mM ATP, 1U/ml hexokinase and 1U/ml glucose-6-
phosphate dehydrogenase). During this time, glucose is
phosphorylated to glucose-6-phosphate (G6P), and the latter
is then oxidized to 6-phosphate glucoronate in the presence
of NAD. Conversion of NAD to NADH was measured by
the increase in absorbance at 340 nm, which is directly pro-
portional to the glucose concentration. To calculate glucose
consumption, values were compared with media (RPMI or
IMDM) glucose levels and corrected for cell growth.
2.3. Flow Cytometry. Apoptosis was assessed by ﬂuorescence-
activated cell sorting (FACS) after treatment with MP and
2-DG or the combination of drugs. Cells were harvested,
pelleted by centrifugation, and washed with phosphate-
buﬀered saline (PBS). Subsequently, leukemic cells were
resuspended in 100μl of binding buﬀer (1.4M NaCl,
25mM CaCl, 0.1M Hepes; pH 7.4) and stained with
FITC-labeled Annexin-V-ﬂuorescein isothiocyanate (Bio-
tium, Hayward, CA, USA) and 7-Aminoactinomycin D
(7-AAD) according to the manufacturer’s protocol (BD
Biosciences, Mississauga, ON) and analyzed on a Becton-
Dickinson LSR II ﬂow cytometer using BD FACSDiva soft-
ware (version 6.1.3; Becton Dickinson AG, Allschwil,
Switzerland) and FlowJo software (version 5.4+; Three Star
Inc., Ashland, OR, USA). PE Active Caspase-3 Apoptotic
kit (BD Pharmigen, San Diego, CA, USA) according with
manufacture’s instruction was used to conﬁrm apoptosis.
Flow cytometry analysis measurements were performed in
singlet with three repetitions of each individual experiment.
2.4. Nucleofection. Silencing ofHKII gene by small interfering
RNA (siRNA) was performed by nucleofection using the
Amaxa Nucleofector II (Amaxa Biosystems, Cologne,
Germany), following the manufacturer’s instructions. Each
sample was transfected with 300 nM siRNA (HKII: siRNA
IDs 6562) (Ambion, Applied Biosystem, USA) using the
program X-01 of the Nucleofector II. The transfection
eﬃciency was evaluated by quantitative RT-PCR after 24 h.
Following the same procedure, protein extracts were ana-
lyzed by Western blotting 48 h after transfection, and the
impact on cell viability was evaluated by using the MTS assay
(Promega, Madison, WI, USA).
2.5. Microarray Analysis. The raw data in the form of
Aﬀymetrix.CEL hybridisation ﬁles from the dataset of
Haferlach et al. [15] were downloaded from the ArrayEx-
press database (accession E-GEOD-13159). The data was
background-corrected and normalized using the Robust
Microarray Analysis method. Gene summarization was done
using the alternative CDF ﬁles provided by Dai et al. [16].
Diﬀerential gene expression of 121 ch-ALL samples carrying
the translocation t(9;22) (Philadelphia chromosome positive)
and 236 ch-ALL samples without this translocation com-
pared to 72 healthy bone marrow samples was calculated
using the limma R-package.
2.6. Metabolite Proﬁling.A total of 234 samples from SUP-15,
SD1, and REH leukemia cell lines were treated with vehicle
(Benzyl alcohol, AB), MP, and 2-DG or the combination
for 0, 6, 12, 18, 24, and 48 h. Cells were extracted using a
modiﬁed version of a previously described protocol. Brieﬂy,
rapid inactivation of metabolism was obtained by a two-
step process consisting of initial quenching of the cells,
followed by extraction of the metabolites. Quenching
procedure: 2× 106 cells were washed twice with 150μl of
ammonium carbonate (75mM, pH 7.4) prewarmed at 75°C
and shaken on a heating block. Cells were pelleted by
centrifugation and snap-frozen in liquid nitrogen. For
metabolite extraction, pellets were treated twice with 150μl
of hot extraction solution (75°C, 70% v/v pure ethanol) and
placed in a heating block (75°C) for 3 minutes. The collected
supernatants were completely dried under vacuum. Dry
extracts were stored at −80°C until metabolomics analy-
sis. Nontargeted metabolome proﬁling was done by ﬂow
injection—time-of-ﬂight analysis in negative mode on an
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Agilent 6550 QTOF instrument (Agilent, Santa Clara
CA, USA).
2.7. Clustering Analysis and Metabolite Pathway Analysis.
The ion intensities were ﬁrst log-transformed and then
averaged over all technical replicates per condition, result-
ing in a matrix with 60 columns for 4 treatments, 3 cell
lines and 5 time points, and 827 rows for as many ions.
For each noncontrol condition—that is, any treatment
with MP, 2-DG, or 2-DG+MP—log-fold change values
were calculated by subtracting the log-transformed intensi-
ties from the corresponding, that is, same cell line and time
point, control sample. This operation resulted in a matrix
with 45 columns—3 cell lines x 3 treatments x 5 time
points—and 827 rows. Of these 827 ions, we retained only
those with signiﬁcantly changing intensities, either over time
or across diﬀerent treatments compared to the control treat-
ment, using the limma method [17]. Using an adjusted
p value cutoﬀ of 0.01, 649 ions were retained. Next,
k-medoids clustering was performed to detect groups of sim-
ilarly regulated ions using the correlation distance as distance
metric. Using the silhouette width quality score, the optimal
number of clusters to create was found to be 5. We then used
the SetRank algorithm to look for overrepresented pathways
in each cluster, using metabolite annotation from the KEGG
and Reactome databases [18, 19].
2.8. High-Throughput Protein Kinase Inhibitors Screen. REH
and SD1 leukemia cells were screened with a library of 365
GlaxoSmithKline Published Kinase Inhibitor Set (GSK, PLC
United Kingdom) [20]. The cells were plated at a minimum
density of 30,000 cells per well, in 96-well plates in tripli-
cates. Cells were treated with MP (150μg/ml for REH and
100μg/ml for SD1) alone and/or in combination with the
kinase inhibitors at the ﬁnal concentration of 1μM. Dimethyl
sulfoxide (DMSO, Sigma-Aldrich Chemie Gmbh, Buchs,
Switzerland) as a negative control was added to each plate
of the library. Validation of the hit candidates was evaluated
after 72 h using the MTS assay. SB-360741 a 3-anilino-4-
arylmalemide, GSK-3 inhibitor was selected and further
validated in SD1 and REH cell lines.
2.9. Statistical Analysis. All statistics were performed in
GraphPad Prism software (La Jolla, CA, USA). The statistical
signiﬁcance of diﬀerences between groups was assessed
by two-way analysis of variance (ANOVA) correct for
Bonferroni’s multiple comparison test. p values of <0.05
were considered signiﬁcant.
3. Results
3.1. 2-DG Modulates MP-Induced Cytotoxicity in Resistant
ch-ALL Cell Lines. 2-DG, a synthetic glucose analog with a
primary function to inhibit glycolysis, has been reported to
synergize with standard anticancer treatments in the induc-
tion of cell death in several carcinoma types [10, 21, 22].
MP resistance in leukemia has been associated with an
increased expression of genes involved in glucose metabo-
lism. Moreover, inhibition of glycolysis was shown to
sensitize leukemia cells to prednisone [5]. Single treatment
with MP was administrated to three leukemia cell lines, and
according to their responses, they were classiﬁed as sensitive
(SUP-B15), intermediate (SD1), and resistant (REH) cells
toward MP (Figure 1). To determine the eﬀects of 2-DG,
SUP-B15, SD1, and REH, cells were exposed to increasing
concentration of the glucose analog and their growth and
cytotoxic responses were assessed (Figure 1). SUP-B15 and
SD1 displayed a dose-dependent decrease in cell viability
(Figures 1(a) and 1(b)) in response to the glycolysis inhibitor.
The REH cell line showed a higher resistance towards 2-DG
(Figure 1(c)). Thus, it was necessary to increase the dose of
the glucose analog in order to obtain the same biological
eﬀect. To further investigate if the observed synergism of
chemotherapy and 2-DG reported in carcinoma cells could
also be observed in the case of GCs sensitization towards
MP, 2-DG was administrated with sublethal concentrations
of MP. Coincubation of 2-DG and MP displayed increased
cytotoxicity in all leukemia cell lines tested. All three
leukemia cell lines displayed synergistic eﬀects between the
two drugs, with values of Fsyn = 0 86, 0.95, and 0.58 for
SUP-B15, SD1, and REH, respectively (Figure 2). Moreover,
SD1 displayed a dose-dependent viability decrease upon
combinatorial treatment with all three concentrations of
2-DG tested (Figure 2(b)), while the eﬀect on REH cell line
was independent of the dose of 2-DG (Figure 2(c)). In con-
trast, the synergistic eﬀect in SUP-B15 was observed only at
the higher concentration of 2-DG (0.25mM) (Figure 2(a)).
3.2. 2-DG Inhibits Glucose Consumption, Utilization, and
Uptake. To determine whether metabolic changes are associ-
ated with glucocorticoid resistance in ch-ALL and to further
investigate the hypothesis that this cancer relies on glycolysis
to produce ATP and biomass, we analyzed the glucose uptake
in a panel of leukemia cell lines (Figure 3). The cells were
cultured in normal media in the presence or absence of single
drugs or combinatorial drug treatments. Despite the broad
spectrum of treatment concentrations, the SUP-B15 cell line
did not display any diﬀerences in glucose uptake upon
treatment with MP (Figure 3(a)), 2-DG (Figure 3(b)), or
the combination suggesting that the survival of this cell line
does not rely exclusively on glycolysis (Figure 3(d)). This
observation can be in part explained by SUP-B15 sensitivity
to MP. In contrast, SD1 and REH cells displayed an increase
in glucose consumption and a signiﬁcant rescue of the glu-
cose uptake upon 2-DG treatment (Figures 3(b) and 3(c))
at the concentration of 1mM. Moreover, the combinatorial
treatment of MP (50μg/ml) and 2-DG (0.5mM) was able
to revert the glucose uptake signiﬁcantly, after 96 h exposure
(Figures 3(e) and 3(f)).
3.3. 2-DG Sensitizes Resistant ch-ALL Cell Lines to MP-
Induced Apoptosis. To analyze the mechanism of action of
the combinatorial treatment of 2-DG and MP as a cause of
cell viability decrease, a ﬂow cytometry analysis of apoptotic
markers (Annexin-V, 7-AAD) was performed. Induction
of apoptosis was detected in all three leukemia cell lines
after 12 h and 24h (Figures 4(a) and 4(b)). An increase
in early apoptosis (Annexin-V-positive cells) was observed
after 12 h in the intermediate and resistant cell lines
3Oxidative Medicine and Cellular Longevity
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Figure 1: Eﬀects of MP and 2-DG single treatment in a panel of ch-ALL cell lines. Cell viability was evaluated in (a) SUP-B15, (b) SD1, and
(c) REH cells treated for 72 h with MP and 2-DG at the indicated concentrations. Error bars represent the SD of the mean of three
independent experiments (n = 3).
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(Figure 4(a)). Unlike SD1 and REH, SUP-B15 displayed an
increase in late apoptosis upon 12 h of treatment. Inter-
estingly, combinatorial treatments induced early and late
apoptosis in all three leukemia cell lines (Figure 4(b)). Taken
together, these results conﬁrm that MP treatment in combi-
nation with 2-DG not only leads to increased apoptotic
activity in leukemia cell lines, but also tends to overcome
MP-resistance in SD1 and REH by inducing a decrease in
cell viability. This supports the hypothesis that inhibition
of metabolism with 2-DG impairs proliferation and triggers
cell death in ch-ALL cells. To conﬁrm our data, we measured
apoptotic markers upon single and combinatorial treatment
at the protein level. An induction of apoptosis was observed
in all three leukemia cell lines upon 24 h of treatment, indi-
cated by the increased levels of cleaved PARP protein, a
nuclear enzyme involved in DNA repair (Figure 4(c)).
SUP-B15 displayed a similar induction of cleaved PARP
upon single or combinatorial treatment while SD1 demon-
strated an induction of apoptosis upon 2-DG treatment
and the combinatorial treatment (Figure 4(c)). REH dis-
played apoptosis only following combinatorial treatment
(Figure 4(c)). Moreover, the levels of active caspase-3 were
assessed after 24 h of treatment. In line with our previous
results, activation of caspase-3 in the SUP-B15 cell line was
found upon all treatment conditions, while in SD1 and
REH, a signiﬁcant activation was observed only upon
combinatorial treatment (Figure 4(d)). Regression analysis
conﬁrmed that the reduction in cell viability is in part due
to the induction of apoptosis (Additional ﬁle 1: Figure S1
available online at https://doi.org/10.1155/2017/2487297).
3.4. 2-DG-Induced Cytotoxicity Is Exerted in a Hexokinase-
Independent (HK) Manner in Leukemia Cell Lines. We used
the cDNA microarray data set from Haferlach et al. [15] to
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Figure 2: Synergistic eﬀect of MP and 2-DG in ch-ALL cell lines. The responses of a panel of leukemia cell lines to MP alone and in
combination with 2-DG: (a) 0.1mM, 0.2mM, and 0.25mM of 2-DG for SUP-B15 and (b, c) 0.5mM, 1mM, and 2.5mM of 2-DG for SD1
and REH was measured after 72 h using the MTS assay. Cell viability was normalized to untreated cells (100%). Data represent the SD of
the mean of three independent experiments (n = 3). ∗p ≤ 0 05, ∗∗p ≤ 0 01, ∗∗∗p ≤ 0 001 compared to single treatment (−2-DG) as
determined by two-way ANOVA analysis of variance using Bonferroni’s multiple comparison test.
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analyze diﬀerences in gene expression in patients of two
ch-ALL subgroups in comparison with healthy bone
marrow samples. The wide cohort of ch-ALL patient sam-
ples analyzed in our laboratory (data not shown) displayed
a general downregulation of the genes involved in the gly-
colytic pathway (Additional ﬁle 1: Figures 2a and 2b). Sur-
prisingly, all three hexokinase isoforms (HKI, HKII, and
HKIII) are signiﬁcantly downregulated in both ch-ALL
subgroups examined compare to healthy bone marrow
(all p value >10−10) (Additional ﬁle 1: Figure 2a). The
hexokinase isoforms II (HKII) and III (HKIII) are enzymes
responsible for the conversion of glucose to glucose-6-
phosphate (G6P), which is considered as the ﬁrst limiting
step of glycolysis. In line with this result, further evidence
revealed that in our panel of leukemia cell lines, the
expression of HK isoforms was downregulated (Additional
ﬁle 1: Figure 2c). We thus speculated that in our leukemia
in vitro model, HKII is not required for 2-DG-mediated
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Figure 3: Glucose consumption in a panel of ch-ALL cell lines. The absolute glucose levels were measured in the cell media after incubation
with MP, 2-DG, or combinatorial treatment. Kinetic measurements of glucose uptake were performed; only data from 96 h are shown.
(a) SUP-B15, (b) SD1, and (c) REH cell lines were treated with increasing concentration of MP (left graph) and 2-DG (right graph).
RPMI and IMDM controls represent the amount of glucose present in the culture medium incubated for 96 h in the absence of
treatment. The eﬀects of combined drug treatments on glucose levels are shown in (d), (e), and (f) for SUP-B15, SD1, and REH,
respectively. The conversion of glucose to glucose-6-phosphoglucoronate (G6P) and NADH was evaluated. The concentration of
NADH was measured. Graphs represent the SD of the mean of at least two independent experiments (n = 2). ∗p ≤ 0 05 using two-way
analysis of variance (ANOVA) using Bonferroni’s multiple comparison test.
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apoptosis induction. Since leukemic cell can circulate freely
through normoxic and hypoxic environments, we investi-
gated whether in normal and decreasing oxygen tension, 2-
DG leads to the same biological eﬀect. Upon treatment with
2-DG, the cells were incubated either in normoxia or in
hypoxia (pO2 1%). No signiﬁcant diﬀerences in the impact
of 2-DG on cell viability were observed (Additional ﬁle 1:
Figure 3). Thus, 2-DG treatment leads to cell viability impair-
ment independently of the oxygen levels in ch-ALL cells. To
conﬁrm that HK is not crucial for the eﬀects of 2-DG in
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Figure 4: Induction of apoptosis upon MP, 2-DG, and combinatorial treatments. Apoptotic markers analysed by ﬂuorescence-activated-cell-
sorting (FACS) and western blot in a panel of ch-ALL after treatment with MP and 2-DG. FACS quantiﬁcation of single (light grey) or double
positive cells for Annexin-V and 7-AAD (white) after (a) 12 h and (b) 24 h treatment with MP and 2-DG. The percentage of living cells is
represented in dark grey color. (c) Protein expression analysis by Western blot of cleaved-PARP in leukemia cell lines treated with MP,
2-DG, and MP+2-DG for 24 h is shown. (d) Caspase-3 activation was assessed by FACS in all three leukemia cell lines treated as
described previously. Error bars represent the SD of the mean of at least two independent experiments (n = 2). ∗∗p ≤ 0 01, ∗∗∗p ≤ 0 001,
two-way analysis of variance (ANOVA) using Bonferroni’s multiple comparison test.
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leukemia cell lines, we performed HKII silencing in all three
leukemia cell lines (Figure 5 and Additional ﬁle 1: Figure 4).
Due to low transfection eﬃciency in SUP-B15 and SD1
cell lines and since REH appeared to be the most resistant
cell line, further experiments were carried out only in
REH. The siRNA transfection eﬃciency at the mRNA level
was measured after 24 h (Figure 5(a) and Additional ﬁle 1:
Figure 4b) and conﬁrmation of HKII silencing at the pro-
tein level was measured after 48 h by Western blot analysis
(Figures 5(a) and 5(b)). To gain further insight on the
role of HKII in REH cells, we performed cell viability
assays after HKII knockdown. Silencing HKII did not sig-
niﬁcantly change the treatment response to either 2-DG
(Figure 5(c)) or MP (Figure 5(d)), implying that the cytotoxic
eﬀect of 2-DG in this ch-ALL cell line is not dependent on its
ability to inhibit glycolysis. Therefore, we focused our
attention on identifying additional molecular targets of
2-DG in leukemia cell lines.
3.5. 2-DG Interferes with N-Linked Glycosylation (NLG) and
Induces Changes in the Metabolic Proﬁle of Leukemic Cells
In Vitro. 2-DG is known as a structural analog of mannose
and acts as a potent inhibitor of N-linked glycosylation
(NLG), by competition with the endogenous substrate and
by fraudulent incorporation into dolichol-pyrophosphate
(lipid)-linked oligosaccharides, which are the precursors of
NLG [23]. To investigate whether the antiproliferative eﬀects
of 2-DG in normoxia predominantly occur through inhibi-
tion of NLG and not through an HK-dependent block in
glycolysis, we performed a cytotoxicity assay in the presence
or absence of mannose (2.5mM) (Figure 6(a)). Mannose
treatment signiﬁcantly reversed 2-DG-induced cytotoxicity,
leading to the hypothesis that the eﬀects of 2-DG in leuke-
mia cells in normoxia are primarily due to interference
with NLG. Moreover, a metabolomics analysis of the leu-
kemia cell lines under study showed that a signiﬁcant
decrease in several metabolites involved in hexosamine
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biosynthesis pathway (HBP) and in the genesis of N-linked
glycans was observed upon 48 h of combinatorial treatment
(Figure 6(b)). UDP-N-acetyl-hexosamine, N-acetyl-hexosa-
mine-phosphates, and UDP-hexosamine, which are all
involved in the generation of glycosaminoglycans, proteogly-
cans, and glycolipids, were signiﬁcantly downregulated upon
combinatorial treatment (all p value <10−15) (Figure 6(c)). As
a consequence, the glycans are not transferred to the nascent
products (e.g., glycoprotein), leading to a block in protein
synthesis. As can be seen from Figure 6(c), the general trend
of metabolites in UDP-N-acetyl-hexosamine pathway is
upregulated at 24h and downregulated at 48h.
In addition, depending on the cell line used, UDP-N-
acetyl-hexosamine levels stay the same or are increased
upon treatment with 2-DG, apart from a slight decrease
at 6 h. However, treatment with MP results in a general
decrease in UDP-N-acetyl-hexosamine, with the exception
of REH. The combined treatment shows a more compli-
cated picture, with generally increased levels of the UDP-
N-acetyl-hexosamine until 24 h and then falling sharply
at 48 h (Figure 6(d)). Together, these results demonstrate
the importance of the deregulation of NLG for the biolog-
ical eﬀects of 2-DG in ch-ALL. It has been described that
impaired NLG leads to the accumulation of unfolded pro-
teins within the endoplasmic reticulum (ER) and to the
induction of the unfolded protein response (UPR) [24–26].
To investigate whether 2-DG treatment alone or in combina-
tion with MP triggers the UPR, leukemia cell lines were
exposed to both drugs as single agents or in combination.
Moreover, treatments with 2-DG and mannose (2.5mM)
were assessed. The impact of these drugs on the UPR was
evaluated by measuring the expression of glucose-regulated
protein 78 (GRP78). In addition, the activation of the
UPR-mediated apoptotic pathway was investigated after
24 h treatment by measuring the expression of DNA
damage-inducible transcript 3 protein (also called CHOP)
(Figure 7). 2-DG alone induced an increase in GRP78
expression leading to the activation of the UPR response,
in particular in the REH resistant cell type (Figure 7(a)).
Surprisingly, in this cell line, the combination of 2-DG
and MP did not lead to any additional increment in the
expression of GRP78. SUP-B15 and SD1 displayed a sig-
niﬁcant increase in the levels of GRP78 in cells cotreated
with 2-DG and MP, compared to single treatments. Sur-
prisingly, in SD1 cells treated with a single dose of MP
(150μg/ml), the level of GRP78 was increased to the same
extent as for the 2-DG single treatment. The activation of
UPR-mediated apoptosis via CHOP was evaluated and we
were able to show that, for SUP-B15 and SD1, the cotreat-
ment with 2-DG and MP led to a signiﬁcant increase in
the expression of CHOP. In contrast, in REH, the same
trend was observed for GRP78, indicating that the treat-
ment with 2-DG alone at 1mM was suﬃcient to increase
the expression of both genes (GRP78 and CHOP). More-
over, mannose (2.5mM) cotreatment with 2-DG was able
to reverse the eﬀects of the latter drug on GRP78 and
CHOP levels in all three leukemia cell lines (Figure 7).
These results indicate that in the leukemic cell lines under
study, 2-DG induces its biological eﬀects by interfering
with NLG leading to UPR induction and subsequent acti-
vation of the UPR-mediated apoptotic pathway.
3.6. High-Throughput Screen with 365 Protein Kinase
Inhibitors Identiﬁes GSK-3 as a Potential Target in
Leukemia. To better understand the mechanism of action
of MP in resistant leukemic cells, we screened 365-protein
kinase inhibitors in SD1 and REH cells. The outcome of the
screen revealed 57 hit compounds, which acted synergisti-
cally with MP. Surprisingly, the majority of those inhibitors
targeted kinases involved in metabolism such as p38-
mitogen-activated protein kinase (p38/MAPK), insulin-like
growth factor-I receptor (IGF-IR), and inhibitor of nuclear
factor kappa-B kinase subunit α and β (IKK-α/β). Interest-
ingly, among these hit compounds, 14 targeted glycogen
synthase kinase-3 (GSK-3). Considering the impact of MP
on cell metabolism and the relevance of GSK-3 inhibition
in our screen, we decided to investigate the role of this kinase
in MP-resistant ch-ALL cells in more detail. We selected the
GSK-3 inhibitor SB-360741, a 3-anilino-4-arylmalemide,
for further analysis, due to its robust synergistic eﬀects
with MP (Fsyn = 0 47 and 0.88 for REH and SD1, resp.)
[27]. A signiﬁcant decrease in REH cell viability was observed
after 72 h of treatment (Figure 8(a)). Comparable results were
observed in the SD1 cell line (data not shown). In order to
investigate the mechanism of cell death induced by MP and
SB-360741, we further analyzed the expression levels of
several apoptotic markers, which revealed that this process
is the main mechanism underlying the observed cytotoxicity.
Upon 24h of single SB-360741 treatment, we observed a
slight increment in cells in early apoptosis (Annexin-V-
positive cells).However, when SB-360741was combinedwith
MP, theapoptotic rate increased signiﬁcantly in comparison to
single treatments (Additionalﬁle 1: Figure 5). Interestingly,we
observed similar biological eﬀects of SB-360741 and 2-DG
when coadministrated with MP. We hypothesize a possible
link between these two pathways. Therefore, we investigated
the eﬀect of 2-DG treatment on GSK-3 activity more in
details. Upon single treatment with 2-DG, GSK-3 phosphor-
ylation status remained unchanged, while the combinatorial
treatment with MP led to the inhibition of GSK-3 activity
via phosphorylation at Ser21 of the α isoform. Together,
these results reveal the existence of 2-DG- and/or GSK-3-
mediated pathway acting synergistically with MP, leading
to the induction of cell death and apoptosis in ch-ALL.
4. Discussion
Within the last years, a large variety of diﬀerent solid
tumors have been associated with increased metabolic activ-
ity [8, 28]. Although there are many examples of solid tumors
having altered metabolism, it has been only recently reported
that this phenomenon also occurs in hematological malig-
nancies [21, 22, 29, 30]. Therefore, targeting the metabolic
pathways could represent an innovative approach to sensitize
leukemic cells to chemotherapeutic drugs and potentially
lead to a better patient outcome [31, 32]. One of the most
important prognostic factors in ch-ALL is the response to
the GCs treatment. Thus, strategies aiming to reverse GCs
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resistance could improve the survival of children suﬀering
from leukemia. Recent data investigating the mechanisms
involved in MP resistance showed a tight correlation between
rapid leukemic growth and a high glycolytic ratio [5]. There-
fore, it is of interest to further analyze the impact of glycolysis
inhibitors in leukemia, since several in vitro and in vivo
studies have demonstrated their eﬃcacy as anticancer drugs
[33]. Moreover, some of these inhibitors have been already
selected as candidates for clinical trials [21, 29, 34, 35]. In
our study, the glucose analog 2-DG was selected principally
because of its strong activity in depleting the production of
ATP at the ﬁrst limiting step of glycolysis. The investigation
of the impact of 2-DG, as an antileukemic agent led us to
the hypothesis that leukemia cells, like solid tumors, might
have an altered metabolism, a phenomenon termed as
“aerobic glycolysis” [36]. Indeed, the inhibition of the glucose
consumption by 2-DG was paralleled by a decrease in cell
viability and enhanced apoptosis in our in vitro leukemia
model. However, a general downregulation of the expression
of genes involved in glycolysis was revealed by cDNA
microarray data analysis performed on a cohort of ch-ALL
patients. A remarkable decrease was particularly observed
in the expression of HK isoforms responsible for the biolog-
ical eﬀect of 2-DG. Furthermore, the cytotoxic eﬀects of
2-DG in cancer appears to be higher under hypoxic condi-
tions, or in cells presenting mitochondrial defects [37, 38].
Since leukemia cells have the capacity to circulate freely
through normoxic and hypoxic environments, it was of
importance to investigate the diﬀerent mechanisms involved
in 2-DG-induced cytotoxicity. Our data show that the
glucose analog acts in an HKII-independent manner to
reduce cell growth in leukemia. In support of our ﬁndings,
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Figure 7: UPR induction by 2-DG in sensitive and resistant ch-ALL cell lines. (a) GRP78/Bip and (b) CHOP mRNA expression was assessed
by real-time RT-PCR (SYBR-green) in leukemia cells treated with 2-DG (dark grey bar), MP (light grey bar), 2-DG+MP (grey striped bar), or
2-DG+Mann (white striped bar). Error bars represent the SD of the mean of at least three independent experiments (n = 3). β-Actin was used
as a control to normalize the samples. p < 0 05 (ns), ∗∗∗p ≤ 0 001 using two-way analysis of variance (ANOVA) with Bonferroni’s multiple
comparison test.
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several reports have suggested a more complex mechanism of
action of 2-DG [12, 39, 40]. In this context, we were able to
show that a signiﬁcant fraction of the 2-DG-mediated cell
death can be rescued by coadministration of exogenous
mannose. These data suggest that the observed antileukemic
eﬀects of 2-DG potentially involve NLG. By interfering with
this process and consequently with protein folding, 2-DG
promotes ER stress leading to UPR induction and protein
synthesis inhibition [41, 42]. In addition, prolonged ER stress
triggers an irreversible UPR-mediated apoptotic response
[43]. The deregulation of NLG via 2-DGmight serve as a sen-
sor linking metabolism with the activation of oncogenic
pathways. In line with this, a screen of 365 protein kinase
inhibitors performed in two leukemia cell lines revealed that
most of the kinases synergistically acting with MP were
involved in metabolism. The selected kinase inhibitor target-
ing GSK-3 (SB-360741) was able to induce the same biologi-
cal eﬀects as 2-DG in combination with MP. GSK-3 is known
to regulate apoptosis and proliferation in cancer and its role
appears to be distinct, not only between physiological and
pathological conditions but also depending on cell type and
tissue context [44–46]. Moreover, in neuroblastoma, 2-DG
exposure triggered an energy depletion in a GSK-3-
mediated manner resulting in attenuation of the mitochon-
drial biogenesis, a particular form of stress adaptation [47].
In leukemia cell lines, we were unable to show a direct regu-
lation of GSK-3 by 2-DG. Nevertheless, the combinatorial
treatment of the glucose analog with MP highly aﬀected
the activity of the kinase. In conclusion, this study pro-
vides new insights into the intimate connection between
GCs resistance and altered metabolism in ch-ALL. There-
fore, it will be of a great interest to investigate alternative
roles of 2-DG in a wider metabolic context, besides its
function as a glucose analog. In addition, investigating of
the role of GSK-3 in leukemia metabolism will provide
further essential knowledge about the mechanisms under-
lying MP resistance. This research work provides evidence
of the intimate connection between GCs resistance and
altered metabolism in ch-ALL. Therefore, the current and
the future challenge in the ﬁeld of cancer metabolism is
to dissect these complex metabolic changes and interpret
them as a result of global metabolic interactions.
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